KZIA
Kazia Therapeutics Limited [KZIA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KZIA Stock Summary
In the News
KZIA Financial details
Company Rating
-
Market Cap
9.98M
Income
-39.07M
Revenue
-2.9M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-5.5
Forward P/E
-
PEG
0.64
P/S
22176.38
P/B
9.34
P/C
-
P/FCF
-0.81
Quick Ratio
0.71
Current Ratio
1.42
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.26
EPS next Y
-
EPS next Q
-
EPS this Y
-94.09%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-42.76%
Revenue last 5Y
-18.73%
Revenue Q/Q
-
EPS Q/Q
-65.81%
-
-
-
-
SMA20
19.37%
SMA50
-14.31%
SMA100
-54.99%
Inst Own
-
Inst Trans
-
ROA
-73%
ROE
-346%
ROC
-1.18%
Gross Margin
100%
Oper. Margin
-4342901%
Profit Margin
-3680788%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.19-1.68
52W High
-
52W Low
-
RSI
75.72
Rel Volume
0.04
Avg Volume
900.43K
Volume
37.84K
Perf Week
43.05%
Perf Month
60.66%
Perf Quarter
-70.19%
Perf Half Y
-78.34%
-
-
-
-
Beta
2.113
-
-
Volatility
0.74%, 0.52%
Prev Close
-0.19%
Price
5.35
Change
11%
Company Profile
- Volume Average 900.43K
- Market Capitalization 9.98M
- Employee 9
- CEO Dr. John Edwin Friend II, M.D.
- Headquarters Sydney,NSW,AU
- IPO Date 1999-01-06
-
Website
https://www.kaziatherapeutics.com 
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
